Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Clin Gastroenterol Hepatol ; 11(7): 815-23.e1-3, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23333663

RESUMEN

BACKGROUND & AIMS: Although home parenteral nutrition (PN) can save the lives of patients with massive bowel loss that results in short-bowel syndrome and intestinal failure, quality of life is impaired by PN and its complications. We examined the 12-month tolerability and efficacy of teduglutide to reduce PN dependency. METHODS: Patients who received teduglutide (0.05 or 0.10 mg/kg/d) for 24 weeks in a randomized controlled trial were eligible for a 28-week double-blind extension study; 52 patients were given 52 weeks of the same doses of teduglutide. We investigated the safety, tolerability, and clinical efficacy (defined as a clinically meaningful ≥20% reduction in weekly PN volume from baseline) at week 52. RESULTS: The most common adverse events reported included headache (35%), nausea (31%), and abdominal pain (25%); 7 patients withdrew because of adverse events (gastrointestinal disorders in 4). Both groups had progressive reduction in PN. At week 52, 68% of the 0.05-mg/kg/d and 52% of the 0.10-mg/kg/d dose group had a ≥20% reduction in PN, with a reduction of 1 or more days of PN dependency in 68% and 37%, respectively. Four patients achieved complete independence from PN. CONCLUSIONS: For patients with short-bowel syndrome intestinal failure, the efficacy of teduglutide was maintained over 52 weeks and the safety profile was sufficient for it to be considered for long-term use. Further studies are needed to determine whether these effects will translate into improved quality of life and reduced PN complications. ClinicalTrials.gov number, NCT00172185.


Asunto(s)
Fármacos Gastrointestinales/efectos adversos , Fármacos Gastrointestinales/uso terapéutico , Nutrición Parenteral , Péptidos/efectos adversos , Péptidos/uso terapéutico , Síndrome del Intestino Corto/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto Joven
2.
Gastroenterology ; 143(6): 1473-1481.e3, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22982184

RESUMEN

BACKGROUND & AIMS: Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion. These factors could increase fluid and nutrient absorption in patients with short bowel syndrome with intestinal failure (SBS-IF). We performed a prospective study to determine whether teduglutide reduces parenteral support in patients with SBS-IF. METHODS: We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily. Parenteral support was reduced if 48-hour urine volumes exceeded baseline values by ≥ 10%. The primary efficacy end point was number of responders (patients with >20% reduction in parenteral support volume from baseline at weeks 20 and 24). RESULTS: There were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (13/43 [30%]; P = .002). At week 24, the mean reduction in parenteral support volume in the teduglutide group was 4.4 ± 3.8 L/wk (baseline 12.9 ± 7.8 L/wk) compared with 2.3 ± 2.7 L/wk (baseline 13.2 ± 7.4 L/wk) in the placebo group (P < .001). The percentage of patients with a 1-day or more reduction in the weekly need for parenteral support was greater in the teduglutide group (21/39 [54%]) than in the placebo group (9/39 [23%]; P = .005). Teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass. The distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide (n = 2) and placebo (n = 3). CONCLUSIONS: Twenty-four weeks of teduglutide treatment was generally well tolerated in patients with SBS-IF. Treatment with teduglutide reduced volumes and numbers of days of parenteral support for patients with SBS-IF; ClinicalTrials.gov Number, NCT00798967.


Asunto(s)
Absorción Intestinal/fisiología , Enfermedades Intestinales/tratamiento farmacológico , Intestinos/fisiopatología , Nutrición Parenteral , Péptidos/uso terapéutico , Síndrome del Intestino Corto/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Citrulina/sangre , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Determinación de Punto Final , Femenino , Humanos , Inyecciones Subcutáneas , Enfermedades Intestinales/sangre , Enfermedades Intestinales/fisiopatología , Masculino , Persona de Mediana Edad , Péptidos/administración & dosificación , Péptidos/efectos adversos , Estudios Prospectivos , Síndrome del Intestino Corto/sangre , Síndrome del Intestino Corto/fisiopatología , Resultado del Tratamiento , Grabación en Video , Adulto Joven
3.
Gut ; 60(1): 17-25, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21068130

RESUMEN

BACKGROUND: The indications for intestinal transplantation (ITx) are still debated. Knowing survival rates and causes of death on home parenteral nutrition (HPN) will improve decisions. METHODS: A prospective 5-year study compared 389 non-candidates (no indication, no contraindication) and 156 candidates (indication, no contraindication) for ITx. Indications were: HPN failure (liver failure; multiple episodes of catheter-related venous thrombosis or sepsis; severe dehydration), high-risk underlying disease (intra-abdominal desmoids; congenital mucosal disorders; ultra-short bowel), high morbidity intestinal failure. Causes of death were defined as: HPN-related, underlying disease, or other cause. RESULTS: The survival rate was 87% in non-candidates, 73% in candidates with HPN failure, 84% in those with high-risk underlying disease, 100% in those with high morbidity intestinal failure and 54%, in ITx recipients (one non-candidate and 21 candidates) (p<0.001). The primary cause of death on HPN was underlying disease-related in patients with HPN duration ≤2 years, and HPN-related in those on HPN duration >2 years (p=0.006). In candidates, the death HRs were increased in those with desmoids (7.1; 95% CI 2.5 to 20.5; p=0.003) or liver failure (3.4; 95% CI 1.6 to 7.3; p=0.002) compared to non-candidates. In deceased candidates, the indications for ITx were the causes of death in 92% of those with desmoids or liver failure, and in 38% of those with other indications (p=0.041). In candidates with catheter-related complications or ultra-short bowel, the survival rate was 83% in those who remained on HPN and 78% after ITx (p=0.767). CONCLUSIONS: HPN is confirmed as the primary treatment for intestinal failure. Desmoids and HPN-related liver failure constitute indications for life-saving ITx. Catheter-related complications and ultra-short bowel might be indications for pre-emptive/rehabilitative ITx. In the early years after commencing HPN a life-saving ITx could be required for some patients at higher risk of death from their underlying disease.


Asunto(s)
Intestino Delgado/trasplante , Síndromes de Malabsorción/terapia , Nutrición Parenteral en el Domicilio , Adolescente , Adulto , Niño , Toma de Decisiones , Métodos Epidemiológicos , Femenino , Humanos , Síndromes de Malabsorción/etiología , Síndromes de Malabsorción/mortalidad , Síndromes de Malabsorción/cirugía , Masculino , Nutrición Parenteral en el Domicilio/efectos adversos , Selección de Paciente , Pronóstico , Resultado del Tratamiento , Adulto Joven
4.
Gastroenterology ; 136(3): 824-31, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19046971

RESUMEN

BACKGROUND & AIMS: Tube feeding, recommended for patients with short bowel syndrome in only the postoperative period, has not been compared with oral feeding for absorption. We studied whether tube feeding increased absorption in patients with short bowel syndrome following the postoperative period. METHODS: A randomized crossover study compared absorption between isocaloric tube feeding and oral feeding in 15 short bowel syndrome patients more than 3 months after short bowel constitution. An oral feeding period combined with enriched (1000 kcal * day(-1)) tube feeding was also tested. We measured the net intestinal absorption rates of proteins, lipids, and total calories using elemental nitrogen, Van de Kamer, and bomb calorimetry methods, respectively. RESULTS: Tube feeding increased the mean (+/-SD) percent absorption (P < .001) of proteins (72% +/- 13% vs 57% +/- 18%), lipids (69% +/- 25% vs 41% +/- 27%), and energy (82% +/- 12% vs 65% +/- 16%) compared with oral feeding. In the group given the combined feedings (n = 9), the total enteral intake and net percent absorption increased (P < .001) for proteins (67% +/- 10%), lipids (59% +/- 19%), and total energy (75% +/- 8%) compared with oral feeding. Absorption (kcal * day(-1)) was greater (P < .001) with tube (2225 +/- 457) and combined feedings (2323 +/- 491) than with oral feeding (1638 +/- 458). CONCLUSIONS: In patients with short bowel syndrome, continuous tube feeding (exclusively or in conjunction with oral feeding) following the postoperative period significantly increased net absorption of lipids, proteins, and energy compared with oral feeding.


Asunto(s)
Ingestión de Energía , Nutrición Enteral/métodos , Absorción Intestinal , Síndrome del Intestino Corto/dietoterapia , Adulto , Anciano , Estudios Cruzados , Ingestión de Alimentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Estudios Prospectivos , Síndrome del Intestino Corto/cirugía
5.
Gastroenterology ; 137(1): 101-9, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19344718

RESUMEN

BACKGROUND & AIMS: Chronic intestinal pseudo-obstruction (CIPO) is a rare disorder caused by intestinal dysmotility and characterized by chronic symptoms suggesting bowel obstruction in the absence of fixed, occluding lesions. CIPO has been associated with primary defects of the mitochondrial oxidative phosphorylation pathway, although the frequency of mitochondrial disorders in patients with CIPO is unknown. This study evaluates mitochondrial function in patients with CIPO. METHODS: A retrospective study was performed of data collected from 80 CIPO patients at a tertiary centre over a 25-year period. Mitochondrial disorders were detected by analysis of serum lactate and thymidine phosphorylase activities, brain magnetic resonance images, and muscle biopsies. Genes encoding thymidine phosphorylase, mitochondrial DNA tRNA(leu(UUR)) or tRNA(lys), and DNA polymerase-gamma were analyzed for mutations. RESULTS: Mitochondrial defects were identified in 15 patients (10 women; median age at diagnosis 32 years), representing 19% of the study cohort. All 15 patients had extra-digestive symptoms, 5 had mutations in the thymidine phosphorylase gene, 2 had mutations in tRNA(leu(UUR)), and 5 had mutations in the DNA polymerase-gamma gene. No genetic defect was detected in 3 of the patients with mitochondrial disorders. Patients with mitochondrial CIPO differed from patients without mitochondrial defects in their very severe nutritional status (frequent and long-term requirement for parenteral nutrition) and poor prognosis (frequent digestive and neurologic complications that led to a high incidence of premature death). CONCLUSION: Mitochondrial disorders seem to be an important cause of CIPO. Patients with CIPO, especially severe cases with associated neurologic symptoms, should be tested for mitochondrial defects.


Asunto(s)
Seudoobstrucción Intestinal/etiología , Enfermedades Mitocondriales/complicaciones , Adolescente , Adulto , Anciano , Biopsia , Niño , Preescolar , Enfermedad Crónica , Pruebas Enzimáticas Clínicas , ADN Polimerasa gamma , ADN Mitocondrial , ADN Polimerasa Dirigida por ADN/genética , Femenino , Pruebas Genéticas , Humanos , Lactante , Seudoobstrucción Intestinal/genética , Seudoobstrucción Intestinal/terapia , Ácido Láctico/sangre , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Enfermedades Mitocondriales/diagnóstico , Enfermedades Mitocondriales/genética , Enfermedades Mitocondriales/terapia , Mutación , Estado Nutricional , Nutrición Parenteral , Pronóstico , Estudios Prospectivos , Aminoacil-ARN de Transferencia/genética , Estudios Retrospectivos , Factores de Riesgo , Timidina Fosforilasa/sangre , Timidina Fosforilasa/genética , Adulto Joven
6.
Am J Physiol Gastrointest Liver Physiol ; 297(1): G116-23, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19389806

RESUMEN

In short bowel syndrome (SBS), although a remaining colon improves patient outcome, there is no direct evidence of a mucosal colonic adaptation in humans. This prospective study evaluates morphology, proliferation status, and transporter expression level in the epithelium of the remaining colon of adult patients compared with controls. The targeted transporters were Na+/H+ exchangers (NHE2 and 3) and oligopeptide transporter (PepT1). Twelve adult patients with a jejuno-colonic anastomosis were studied at least 2 yr after the last surgery and compared with 11 healthy controls. The depth of crypts and number of epithelial cells per crypt were quantified. The proliferating and apoptotic cell contents were evaluated by revealing Ki67, PCNA, and caspase-3. NHE2, NHE3, PepT1 mRNAs, and PepT1 protein were quantified by quantitative RT-PCR and Western blot, respectively. In patients with SBS compared with controls, 1) hyperphagia and severe malabsorption were documented, 2) crypt depth and number of cells per crypt were 35% and 22% higher, respectively (P < 0.005), whereas the proliferation and apoptotic levels per crypt were unchanged, and 3) NHE2 mRNA was unmodified; NHE3 mRNA was downregulated near the anastomosis and unmodified distally, and PepT1 mRNA and protein were unmodified. We concluded that, in hyperphagic patients with SBS with severe malabsorption, adaptive colonic changes include an increased absorptive surface with an unchanged proliferative/apoptotic ratio and well-preserved absorptive NHE2, NHE3, and PepT1 transporters. This is the first study showing a controlled nonpharmacological hyperplasia in the colon of patients with SBS.


Asunto(s)
Proliferación Celular , Colon/fisiopatología , Mucosa Intestinal/fisiopatología , Síndrome del Intestino Corto/fisiopatología , Intercambiadores de Sodio-Hidrógeno/metabolismo , Simportadores/metabolismo , Adaptación Fisiológica , Anciano , Apoptosis , Estudios de Casos y Controles , Colon/metabolismo , Colon/patología , Colon/cirugía , Femenino , Humanos , Hiperfagia/metabolismo , Hiperfagia/patología , Hiperfagia/fisiopatología , Hiperplasia , Absorción Intestinal , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Mucosa Intestinal/cirugía , Masculino , Persona de Mediana Edad , Estado Nutricional , Transportador de Péptidos 1 , Estudios Prospectivos , ARN Mensajero/metabolismo , Síndrome del Intestino Corto/metabolismo , Síndrome del Intestino Corto/patología , Intercambiador 3 de Sodio-Hidrógeno , Intercambiadores de Sodio-Hidrógeno/genética , Simportadores/genética , Factores de Tiempo
7.
Gastroenterology ; 135(1): 61-71, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18471440

RESUMEN

BACKGROUND & AIMS: The US Medicare indications for intestinal transplantation are based on failure of home parenteral nutrition. The American Society of Transplantation also includes patients at high risk of death from their primary disease or with high morbidity intestinal failure. A 3-year prospective study evaluated the appropriateness of these indications. METHODS: Survival on home parenteral nutrition or after transplantation was analyzed in 153 (97 adult, 56 pediatric) candidates for transplantation and 320 (262 adult, 58 pediatric) noncandidates, enrolled through a European multicenter cross-sectional survey performed in 2004. Kaplan-Meier and chi-square test statistics were used. RESULTS: The 3-year survival was 94% (95% CI, 92%-97%) in noncandidates and 87% (95% CI, 81%-93%) in candidates not receiving transplants (P = .007). Survival was 80% (95% CI, 70%-89%), 93% (95% CI, 86%-100%), and 100% in parenteral nutrition failure, high-risk primary disease, and high-morbidity intestinal failure, respectively (P = .034). Fifteen candidates underwent transplantation. Six died, including all 3 of those who were in hospital, and 25% of those who were at home at time of transplantation (P = .086). Survival in the 10 patients receiving a first isolated small bowel transplant was 89% (95% CI, 70%-100%), compared with 85% (95% CI, 74%-96%) in the candidates with parenteral nutrition failure not receiving transplants because of central venous catheter complications, or 70% (95% CI, 53%-88%) in those with parenteral nutrition-related liver failure (P = .364). CONCLUSIONS: The results confirm home parenteral nutrition as the primary therapeutic option for intestinal failure and support the appropriateness and potential life-saving role of timely intestinal transplantation for patients with parenteral nutrition failure.


Asunto(s)
Enfermedades Gastrointestinales/mortalidad , Intestinos/trasplante , Nutrición Parenteral en el Domicilio/mortalidad , Trasplante/mortalidad , Adolescente , Adulto , Niño , Preescolar , Femenino , Estudios de Seguimiento , Enfermedades Gastrointestinales/dietoterapia , Enfermedades Gastrointestinales/cirugía , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Selección de Paciente , Estudios Prospectivos
8.
Am J Gastroenterol ; 104(5): 1262-70, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19367271

RESUMEN

OBJECTIVES: Chronic intestinal pseudo-obstruction (CIPO) is a rare, disabling disorder responsible for motility-related intestinal failure. Because it induces malnutrition, CIPO is a significant indication for home parenteral nutrition (HPN). The objective of the study was to evaluate long-term outcome of CIPO patients requiring HPN during adulthood. METHODS: In total, 51 adult CIPO patients (18 men/33 women, median age at symptom occurrence 20 (0-74) years, 34/17 primary/secondary CIPO) followed up at our institution for HPN management between 1980 and 2006 were retrospectively studied for survival and HPN dependence rates using univariate and multivariate analysis. RESULTS: Follow-up after diagnosis was 8.3 (0-29) years. Surgery was required in 84% of patients. The number of interventions was 3 +/- 3 per patient (mean +/- s.d.), leading to short bowel syndrome in 19 (37%) patients. Actuarial survival probability was 94, 78, 75, and 68% at 1, 5, 10, and 15 years, respectively. Multivariate analysis showed that lower mortality was associated with the ability to restore oral feeding at baseline (hazard ratio (HR) = 0.2 (0.06-0.65), P = 0.008) and symptom occurrence before the age of 20 years (HR=0.18 (0.04-0.88), P = 0.03). Higher mortality was associated with systemic sclerosis (HR=10.4 (1.6-67.9), P = 0.01). Actuarial HPN dependence was 94, 75, and 72% at 1, 2, and 5 years, respectively. CONCLUSIONS: In this large cohort of CIPO adult patients with severe intestinal failure, i.e., those requiring HPN, we found a higher survival probability than previously reported. These results should be taken into account when considering intestinal transplantation.


Asunto(s)
Causas de Muerte , Seudoobstrucción Intestinal/mortalidad , Seudoobstrucción Intestinal/terapia , Nutrición Parenteral en el Domicilio/mortalidad , Síndrome del Intestino Corto/mortalidad , Síndrome del Intestino Corto/terapia , Adolescente , Adulto , Anciano , Análisis de Varianza , Estudios de Cohortes , Procedimientos Quirúrgicos del Sistema Digestivo/efectos adversos , Procedimientos Quirúrgicos del Sistema Digestivo/métodos , Femenino , Motilidad Gastrointestinal , Humanos , Seudoobstrucción Intestinal/diagnóstico , Estimación de Kaplan-Meier , Cuidados a Largo Plazo , Masculino , Manometría , Persona de Mediana Edad , Análisis Multivariante , Nutrición Parenteral en el Domicilio/métodos , Probabilidad , Pronóstico , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Medición de Riesgo , Índice de Severidad de la Enfermedad , Síndrome del Intestino Corto/etiología , Tasa de Supervivencia , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
9.
J Am Coll Surg ; 204(1): 13-21, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17189108

RESUMEN

BACKGROUND: Previous studies showed high prevalence rates of cholelithiasis in patients with home parenteral nutrition (HPN). Our aim was to determine, in an HPN population, the incidence and risk factors for gallstones and sludge and their complications. STUDY DESIGN: Retrospective chart review was conducted in a tertiary care center. One hundred fifty-three consecutive patients who received HPN for longer than 2 months (range 2 to 204 months; median 15 months) between 1985 and 1997 were followed with ultrasonography. Kaplan-Meier curves and log-rank tests were calculated to assess risk factors for gallbladder lithiasis and complications. RESULTS: Thirty-four patients (22%) underwent cholecystectomy before HPN. Of the 119 remaining patients with gallbladder in situ, cholelithiasis appeared during HPN in 45 (38%). The probability of cholelithiasis developing during HPN was estimated to be 6.2%, 21.2%, and 38.7% at 6, 12, and 24 months, respectively. Biliary complications developed in eight patients (7%) during followup. Therapy consisted of endoscopic sphincterotomy (three patients) or operation (five patients) with uncomplicated outcomes except for one patient; no death was observed. Incidence rates of biliary complication during HPN were estimated to be 0.0%, 4.7%, and 10.1% at 6, 12, and 24 months, respectively. Nil or negligible ingesta was the only factor notably associated with incidence of cholelithiasis (p < 0.01) or biliary complications (p < 0.01). CONCLUSIONS: This first incidence study shows a high rate of cholelithiasis and a low rate of complications during HPN. Both events were notably related to nil or negligible ingesta.


Asunto(s)
Enfermedades de los Conductos Biliares/etiología , Colecistitis/etiología , Colelitiasis/complicaciones , Colelitiasis/epidemiología , Nutrición Parenteral en el Domicilio , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades de los Conductos Biliares/epidemiología , Niño , Preescolar , Colecistitis/epidemiología , Colelitiasis/diagnóstico por imagen , Femenino , Francia/epidemiología , Humanos , Incidencia , Lactante , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Ultrasonografía
11.
Gastroenterol Clin Biol ; 30(8-9): 975-85, 2006.
Artículo en Francés | MEDLINE | ID: mdl-17075444

RESUMEN

Chronic intestinal pseudo-obstruction (CIPO) is a disease characterized by episodes resembling mechanical obstruction in the absence of organic, systemic, or metabolic disorders. Pseudo-obstruction is an uncommon condition and can result from primary (40%) or secondary (60%) causes. The most common symptoms are nausea, vomiting, abdominal distension, abdominal pain and constipation or diarrhea. These symptoms are usually present many years before CIPO diagnosis. They can lead to severe electrolyte disorders and malnutrition. Principles for management of patients with CIPO are: to establish a correct clinical diagnosis in excluding mechanical obstruction; to perform a symptomatic and physiologic assessment of the gastrointestinal tract involved; to look for extra-intestinal manifestations, especially for myopathy and neuropathy; to discuss in some cases a surgery for full-thickness intestinal biopsies, and/or a neuromuscular biopsy in case of mitochondrial cytopathy suspicion. The management is primarily focused on symptom control and nutritional support to prevent weight loss and malnutrition. Treatment of CIPO includes prokinetic agents which may help to reduce gastrointestinal symptoms Courses of antibiotics may be needed in patients with symptoms suggestive of bacterial overgrowth. When necessary, enteral nutrition is preferred. In carefully selected patients, feeding jejunostomy with or without decompression gastrostomy may be tried. Long term parenteral nutrition should be reserved for patients who can not tolerate enteral nutrition. Intestinal transplantation can be discussed in selected patients.


Asunto(s)
Seudoobstrucción Intestinal/diagnóstico , Seudoobstrucción Intestinal/terapia , Enfermedad Crónica , Antagonistas de Dopamina/uso terapéutico , Fármacos Gastrointestinales/uso terapéutico , Humanos , Seudoobstrucción Intestinal/etiología , Seudoobstrucción Intestinal/fisiopatología , Apoyo Nutricional
12.
J Neurol ; 252(6): 655-62, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15742109

RESUMEN

We report on four patients with severe polyneuropathy associated with intestinal pseudoobstruction (MNGIE). Three patients presented characteristic supranuclear ophthalmoplegia, and hyperdense signals on T2 weighted cerebral MRI and dystrophic mitochondria in Schwann cells and in endothelial cells in nerve biopsy specimens. Two of these patients had a Charcot-Marie-Tooth (CMT) presentation. All three were heterozygous for a recessively transmitted double substitution in the TP gene: Glu286Lys/Glu289Ala, Asp156Gly/Leu177Pro and Glu289Ala/Gly387Asp. The fourth patient, who was the only patient of this series with an affected sib, had no oculomotor manifestations, nor T2 hyperdense signals on brain MRI, and no TP gene mutation and or morphological abnormalities of mitochondria on electron microscopic examination. He was the only patient of this series with an affected sib. The three patients with the full MNGIE syndrome died before the age of 30 years. Detailed results of nerve pathology show that severe axonal degeneration is associated with segmental abnormalities of the myelin sheath in this syndrome which appears genetically heterogeneous. Our findings suggest that only ophthalmoplegia and hyperdense signals on cerebral MRI are directly related to the mitochondriopathy.


Asunto(s)
Enfermedad de Charcot-Marie-Tooth/patología , Enfermedades Gastrointestinales/patología , Encefalomiopatías Mitocondriales/patología , Adulto , Biopsia/métodos , Cerebelo/patología , Enfermedad de Charcot-Marie-Tooth/complicaciones , Enfermedad de Charcot-Marie-Tooth/genética , Análisis Mutacional de ADN/métodos , Femenino , Enfermedades Gastrointestinales/complicaciones , Enfermedades Gastrointestinales/genética , Humanos , Imagen por Resonancia Magnética/métodos , Masculino , Microscopía Electrónica de Transmisión/métodos , Encefalomiopatías Mitocondriales/complicaciones , Encefalomiopatías Mitocondriales/genética , Músculos/patología , Mutación , Fibras Nerviosas Mielínicas/patología , Fibras Nerviosas Mielínicas/ultraestructura , Conducción Nerviosa/fisiología , Estudios Retrospectivos , Timidina Fosforilasa/genética , Timidina Fosforilasa/metabolismo
13.
Gastroenterol Clin Biol ; 29(8-9): 773-8, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16294144

RESUMEN

We report 3 new cases of Mitochondrial-Neuro-Gastro-Intestinal Encephalomyopathy (MNGIE) (or Pseudo-Obstruction-Leukoencephalopathy-Intestinal-Pseudoobstruction Syndrome [POLIP]), a rare disease that associates chronic intestinal pseudo-obstruction (CIPO) and neurological symptoms. A review of the 72 reported cases together with these 3 cases revealed that this condition was associated with (a) a specific cluster of neurological symptoms including leukoencephalopathy (96%), polyneuropathy (96%), ophthalmoplegia (91%) and hearing loss (55%); (b) a CIPO syndrome with the presence of small bowel diverticulae (53%); and (c) mitochondrial cytopathy in 36 of the 37 tested patients (2 of our 3 cases), and thymidine phosphorylase gene mutations in all the 37 tested patients (2 of our cases). The etiology of POLIP/MNGIE syndrome appears therefore to be due to a mitochondrial cytopathy secondary to thymidine phosphorylase gene mutation(s). In 3 cases, including 2 of our 3 patients, mitochondrial abnormalities were evidenced at the ultrastructural level in digestive smooth muscle demonstrating that the pathogenesis of gastrointestinal involvement was directly related to mitochondrial alterations in digestive smooth muscle cells.


Asunto(s)
Mucosa Intestinal/metabolismo , Seudoobstrucción Intestinal/metabolismo , Mitocondrias/metabolismo , Encefalomiopatías Mitocondriales/metabolismo , Músculo Liso/metabolismo , Adulto , Femenino , Humanos , Seudoobstrucción Intestinal/diagnóstico , Intestinos/patología , Masculino , Encefalomiopatías Mitocondriales/diagnóstico , Encefalomiopatías Mitocondriales/genética , Músculo Liso/patología , Mutación , Timidina Fosforilasa/genética
14.
JPEN J Parenter Enteral Nutr ; 39(6): 719-24, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24913657

RESUMEN

BACKGROUND: Long-term home parenteral nutrition (HPN) may induce liver disorders. Transient elastography (TE) has been proposed as a noninvasive alternative to liver biopsy analysis for assessment of the progression of hepatic fibrosis to cirrhosis. The goal of this study was to compare values from TE measurements to biopsy-determined stages of histologic fibrosis in patients receiving HPN. METHODS: In this multicenter prospective study, patients receiving long-term HPN (≥ 6 months) who required a liver biopsy for clinical reasons were included. TE (FibroScan) values for each patient were compared with the degree of hepatic fibrosis measured from biopsy specimens based on the Brunt classification. TE values were also correlated to biochemical and histologic cholestasis. Two noninvasive indices for predicting liver fibrosis (APRI and FIB-4) were also evaluated. RESULTS: Thirty patients were included in this study (mean age, 42.1 years; 63% male). The mean duration of HPN was 100.7 months; 25 patients had a short bowel and 13 had an intestinal stoma. Biochemical cholestasis was described in 22 patients. Liver histologic features varied among these patients. There was no correlation between the values of TE and the stages of histologic fibrosis, but TE values were significantly correlated to serum bilirubin level and the severity of histologic cholestasis as well as APRI and FIB-4 scores. CONCLUSIONS: In patients with long-term HPN, TE failed to assess the degree of hepatic fibrosis. This could be due to the heterogeneity of liver histologic features observed in these patients and the presence of chronic cholestasis.


Asunto(s)
Colestasis/diagnóstico , Diagnóstico por Imagen de Elasticidad , Cirrosis Hepática/diagnóstico , Nutrición Parenteral en el Domicilio/efectos adversos , Adolescente , Adulto , Anciano , Fosfatasa Alcalina/metabolismo , Aspartato Aminotransferasas/metabolismo , Bilirrubina/sangre , Biopsia , Índice de Masa Corporal , Colestasis/etiología , Estudios de Cohortes , Estudios Transversales , Femenino , Hematócrito , Humanos , Hígado/patología , Cirrosis Hepática/etiología , Masculino , Persona de Mediana Edad , Tiempo de Tromboplastina Parcial , Recuento de Plaquetas , Estudios Prospectivos , Albúmina Sérica/metabolismo , Adulto Joven , gamma-Glutamiltransferasa/metabolismo
15.
Clin Nutr ; 23(6): 1418-25, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15556265

RESUMEN

Long-term (i.e. home) parenteral nutrition has been advocated to be responsible for several metabolic complications among which hepatic disorders have long been the most relevant in view of patients' prognosis. The increased knowledge of the pathophysiologic factors associated to parenteral nutrition-related liver disease as well as the regular improvement of the components and the techniques used for parenteral nutrition leaded progressively to a better prevention of these side effects. This case report focuses on the potential interest of olive oil-based lipid emulsions in home parenteral nutrition patients, in selected situations of home parenteral nutrition-associated metabolic liver disease.


Asunto(s)
Emulsiones Grasas Intravenosas/administración & dosificación , Hepatopatías/etiología , Hígado/metabolismo , Nutrición Parenteral en el Domicilio , Aceites de Plantas/administración & dosificación , Síndrome del Intestino Corto/terapia , Adulto , Humanos , Hígado/enzimología , Hepatopatías/prevención & control , Masculino , Estado Nutricional , Aceite de Oliva , Nutrición Parenteral en el Domicilio/efectos adversos , Resultado del Tratamiento
16.
Am J Clin Nutr ; 100(3): 850-8, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25080462

RESUMEN

BACKGROUND: Benefits of recombinant human growth hormone (rhGH) alone or combined with glutamine in patients with intestinal failure because of short-bowel syndrome remain controversial. OBJECTIVE: We explored effects of rhGH on whole-body protein metabolism in patients with short-bowel syndrome with intestinal failure (SBS-IF) to gain insight into its mechanism of action. DESIGN: Eight stable hyperphagic patients with severe SBS-IF received, in a double-blind, randomized crossover study, low-dose rhGH (0.05 mg · kg⁻¹ · d⁻¹) and a placebo for two 3-wk periods. Leucine and glutamine kinetics under fasting and fed conditions, fat-free mass (FFM), and serum insulin were determined on the final day of each treatment. RESULTS: rhGH increased FFM and nonoxidative leucine disposal (NOLD; an index of protein synthesis) (P < 0.02), whereas FFM and NOLD were correlated in the fed state (r = 0.81, P = 0.015). With rhGH administration, leucine release from protein breakdown (an index of proteolysis) decreased in the fed compared with fasting states (P = 0.012), which was not observed with the placebo. However, the fast-to-fed difference in leucine release from protein breakdown was not significantly different between rhGH and placebo (P = 0.093). With rhGH, the intestinal absorption of leucine and glutamine increased (P = 0.036) and correlated with serum insulin (r = 0.91, P = 0.002). rhGH increased glutamine de novo synthesis (P < 0.02) and plasma concentrations (P < 0.03) in both fasting and fed states. CONCLUSIONS: In SBS-IF patients, feeding fails to decrease proteolysis in contrast to what is physiologically observed in healthy subjects. rhGH enhances FFM through the stimulation of protein synthesis and might decrease proteolysis in response to feeding. Improvements in de novo synthesis and intestinal absorption increase glutamine availability over the physiologic range, suggesting that beneficial effects of rhGH in hyperphagic patients might be achieved without glutamine supplementation.


Asunto(s)
Fármacos Gastrointestinales/uso terapéutico , Glutamina/biosíntesis , Hormona de Crecimiento Humana/uso terapéutico , Absorción Intestinal/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Intestino Delgado/efectos de los fármacos , Síndrome del Intestino Corto/tratamiento farmacológico , Adulto , Composición Corporal/efectos de los fármacos , Estudios de Cohortes , Terapia Combinada , Estudios Cruzados , Método Doble Ciego , Femenino , Glutamina/sangre , Glutamina/metabolismo , Hormona de Crecimiento Humana/genética , Humanos , Hiperfagia/etiología , Resistencia a la Insulina , Mucosa Intestinal/metabolismo , Mucosa Intestinal/fisiopatología , Intestino Delgado/metabolismo , Intestino Delgado/fisiopatología , Masculino , Persona de Mediana Edad , Nutrición Parenteral en el Domicilio , Periodo Posprandial , Biosíntesis de Proteínas/efectos de los fármacos , Proteolisis/efectos de los fármacos , Proteínas Recombinantes/uso terapéutico , Índice de Severidad de la Enfermedad , Síndrome del Intestino Corto/metabolismo , Síndrome del Intestino Corto/fisiopatología , Síndrome del Intestino Corto/terapia , Aumento de Peso/efectos de los fármacos
17.
Clin Nutr ; 32(3): 368-74, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22992308

RESUMEN

BACKGROUND & AIMS: Short bowel syndrome (SBS) is a rare and severe condition where home parenteral nutrition (HPN) dependence can be either permanent or transient. The timing of HPN discontinuation and the survival, according to SBS characteristics, need to be further reported to help plan pre-emptive intestinal transplantation and reconstructive surgery. METHODS: 268 Non-malignant SBS patients have been followed in our institution since 1980. HPN dependence and survival rate were studied with univariate and multivariate analysis. RESULTS: Median follow-up was 4.4 (0.3-24) years. Actuarial HPN dependence probabilities were 74%, 64% and 48% at 1, 2 and 5 years, respectively. In multivariate analysis, HPN dependence was significantly decreased with an early (<6 mo) plasma citrulline concentration >20 µmol/l, a remaining colon >57% (4/7) and a remnant small bowel length >75 cm. Among the 124 patients who became HPN independent, 26.5% did so more than 2 years after SBS constitution. CONCLUSIONS: This study indicates that long-term HPN is required in 47% of SBS patients started on this therapy. HPN independence is significantly associated with the remnant small bowel length, remaining colon and early plasma citrulline concentration. Noteworthy, HPN dependence could be reversed until 5 years after SBS constitution.


Asunto(s)
Nutrición Parenteral en el Domicilio , Síndrome del Intestino Corto/mortalidad , Síndrome del Intestino Corto/terapia , Absorción , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Colon/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Intestino Delgado/fisiopatología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estado Nutricional , Probabilidad , Pronóstico , Estudios Retrospectivos , Síndrome del Intestino Corto/diagnóstico , Tasa de Supervivencia , Adulto Joven
18.
Dig Liver Dis ; 45(2): 110-4, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23149088

RESUMEN

INTRODUCTION: Management of chronic radiation enteritis is often controversial, particularly due to the risk of short bowel syndrome. METHODS: One hundred and seven chronic radiation enteritis patients with short bowel syndrome were studied retrospectively between 1980 and 2009. Survival and home parenteral nutrition dependence rates were evaluated with univariate and multivariate analysis. RESULTS: The survival probabilities were 93%, 67% and 44.5% at 1, 5 and 10 years, respectively. On multivariate analysis, survival was significantly decreased with residual neoplastic disease (HR=0.21 [0.11-0.38], p<0.001), an American Society of Anesthesiologists score >3 (HR=0.38 [0.20-0.73], p=0.004) and an age of chronic radiation enteritis diagnosis >60 years (HR=0.45 [0.22-0.89], p=0.02). The actuarial home parenteral nutrition dependence probabilities were 66%, 55% and 43% at 1, 2 and 3 years, respectively. On multivariate analysis, this dependence was significantly decreased when there was a residual small bowel length >100 cm (HR=0.35 [0.18-0.68], p=0.002), adaptive hyperphagia (HR=0.39 [0.17-0.87], p=0.02) and the absence of a definitive stoma (HR=0.48 [0.27-0.84], p=0.01). CONCLUSION: The survival of patients with diffuse chronic radiation enteritis after extensive intestinal resection was good and was mainly influenced by underlying comorbidities. Almost two-thirds of patients were able to be weaned off home parenteral nutrition.


Asunto(s)
Enteritis/etiología , Nutrición Parenteral en el Domicilio/estadística & datos numéricos , Traumatismos por Radiación/complicaciones , Síndrome del Intestino Corto/etiología , Adulto , Anciano , Anciano de 80 o más Años , Enteritis/mortalidad , Enteritis/cirugía , Femenino , Francia , Humanos , Masculino , Persona de Mediana Edad , Traumatismos por Radiación/mortalidad , Traumatismos por Radiación/cirugía , Estudios Retrospectivos , Síndrome del Intestino Corto/mortalidad , Síndrome del Intestino Corto/cirugía , Análisis de Supervivencia , Resultado del Tratamiento
19.
Am J Clin Nutr ; 97(1): 100-8, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23151533

RESUMEN

BACKGROUND: Segmental reversal of the small bowel (SRSB) is proposed in patients with short-bowel syndrome (SBS) as a rehabilitative therapy, but its effects on absorption have not been studied. OBJECTIVE: We aimed to determine intestinal macronutrient absorption and home parenteral nutrition (HPN) dependence in SBS patients with intestinal failure. DESIGN: We included in a retrospective study all consecutive patients who had an SRSB between 1985 and 2010 and underwent a study of macronutrient absorption. Patients were matched to SBS controls with the same digestive characteristics. Energy and macronutrient absorption were measured. The dependence on HPN was expressed by the number of infusions per week and by the calories infused daily divided by the basal energy expenditure multiplied by 1.5. RESULTS: Seventeen patients who had an SRSB were matched to 17 control patients. Intestinal absorption was higher in the SRSB group for total calories (69.5% compared with 58.0%), fat (48.4% compared with 33.2%), and protein (62.7% compared with 53.4%) (P < 0.05). Median oral autonomy was 100% ± 38.4% in the SRSB group, whereas it was 79% ± 39.6% in the control group (P < 0.05). The number of calories infused was lower in the SRSB group (500 ± 283 compared with 684 ± 541; P < 0.05), as was HPN dependence (33% ± 20% compared with 48% ± 38%; P < 0.05) at the time of the study. CONCLUSION: SRSB allows a gain in macronutrient absorption, which is associated with a lower HPN dependence. To our view, SRSB should be integrated in intestinal rehabilitative adult programs.


Asunto(s)
Absorción Intestinal , Intestino Delgado/metabolismo , Síndrome del Intestino Corto/patología , Síndrome del Intestino Corto/terapia , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Ingestión de Energía , Metabolismo Energético , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Nutrición Parenteral en el Domicilio , Estudios Retrospectivos , Adulto Joven
20.
Clin Nutr ; 31(6): 831-45, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22658443

RESUMEN

BACKGROUND & AIMS: Indications and timing for referral for intestinal transplantation (ITx) were investigated through a review of the literature on home parenteral nutrition (HPN) for benign intestinal failure and a benchmarking to the results of a prospective European survey which evaluated the appropriateness of the current indications for ITx. METHODS: Manuscripts reporting outcomes of adults and children on HPN were retrieved through a PubMed search. Data from the European survey were compared with those on HPN reported in the literature, and with those on ITx reported by the USA registry and by the Pittsburgh center. RESULTS: HPN is a safe treatment with a high probability of survival. The risk of death during HPN is increased by the absence of a specialist team, and appears greater during the early period of treatment. Survival probability is decreased in patients with: age >40 or <2 years, very short bowel remnant, presence of a stoma, chronic intestinal pseudo-obstruction of myopathic origin, systemic sclerosis, radiation enteritis, intra-abdominal desmoids, necrotizing enterocolitis, congenital mucosal diseases. Liver failure is the HPN-related complication with the greatest risk of death. Death related to venous catheter complications is rare. The benchmarking supported the results of the European survey.


Asunto(s)
Benchmarking , Enfermedades Intestinales/terapia , Intestinos/fisiopatología , Nutrición Parenteral en el Domicilio , Recolección de Datos , Bases de Datos Factuales , Europa (Continente) , Humanos , Enfermedades Intestinales/mortalidad , Nutrición Parenteral en el Domicilio/efectos adversos , Probabilidad , Factores de Riesgo , Tasa de Supervivencia , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA